Episode Details
Back to Episodes
Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year
Published 1 year, 5 months ago
Description
CFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic settings.